Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Drug Profile

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881; S-80881-2

Latest Information Update: 10 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advenchen Laboratories; Shanghai Institute of Materia Medica
  • Developer Clovis Oncology; Servier; ShangHai HaiHe Pharmaceutical; Shanghai Institute of Materia Medica
  • Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Apr 2018 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (Advenchen Laboratories pipeline, April 2018)
  • 29 Aug 2017 ShangHai HaiHe Pharmaceutical plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (NCT03260179)
  • 04 May 2017 Servier completes a phase I/II trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in France, Italy and Spain (NCT01283945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top